T cell therapy companies develop treatments that use a patient’s own or donor-derived immune cells to recognise and attack disease. These approaches are primarily used in cancer immunotherapy, with emerging applications across autoimmune and infectious diseases.
This category includes companies working on:
Browse 46 UK T cell therapy companies below.
Multimodal engineered T-cell therapies for treatment-refractory solid cancers
Alceus Bio is a biotechnology company developing next-generation engineered T-cell therapies for solid tumours. Its platform uses generative AI and synthetic biology to design…
CAR-T and bispecific antibody therapies for blood cancers
Hemogenyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for haematological malignancies and autoimmune diseases. Its lead asset,…
In vivo immune cell reprogramming for autoimmune and inflammatory disease
Flip Therapeutics is a biotechnology company developing in vivo immune cell engineering therapies for chronic autoimmune and inflammatory diseases, including multiple sclerosis,…
Engineered T-regulatory cell therapies for immune-mediated diseases
Quell Therapeutics is a clinical-stage UK biotech developing engineered T-regulatory (Treg) cell therapies for immune-mediated diseases, using its proprietary technology to…
Lentiviral vector platform improving yield for advanced cell therapies
Lentitek is a biotechnology company developing proprietary lentiviral vector manufacturing technology for cell and gene therapy developers. Its platform uses novel promoter…
TCR bispecific immunotherapies for cancer and infectious disease
Immunocore is a commercial-stage biopharma developing T cell receptor bispecific immunotherapies. Its lead product tebentafusp received FDA approval in 2022 for metastatic uveal…
Hypoxia-activated CAR-T cell therapy platform for solid tumour cancers
Korecyte Bio is a preclinical-stage cell therapy company developing HypoxiCAR, a modular CAR-T platform for treating solid tumours. The technology uses a dual-sensor genetic…
Full-service CRO for Phase I–IV pharmaceutical and device trials
Clinicology is a contract research organisation providing clinical trial management services to pharmaceutical, biotechnology, and medical device companies. Services span site…
Cancer immunotherapies targeting novel antigens from the dark genome
Enara Bio is a clinical-stage biopharmaceutical company developing cancer immunotherapies directed against Dark Antigens, a class of cancer-specific targets derived from…
Immune cell separation and expansion platform for cell therapies
CoED Biosciences is a biotech developing the Column of Expansion and Differentiation (CoED) platform, a consumable device integrating immune cell separation, functionalisation,…
Immuno-oncology therapies targeting the nfP2X7 cancer receptor
Biosceptre is a UK-headquartered clinical-stage biotechnology company developing cancer therapeutics based on its proprietary nfP2X7 platform. The nfP2X7 receptor is a…
T cell immunotherapies for infectious disease, cancer and autoimmunity
Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing antigen-specific T cell immunotherapies for chronic infectious diseases, autoimmune conditions,…